Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 10/20 | 0.71 |
| ▸ | GLO1 | Q04760 | 5/20 | 0.59 |
| ▸ | SNCA | P37840 | 3/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.59 |
| ▸ | KDR | P35968 | 2/20 | 0.59 |
| ▸ | EP300 | Q09472 | 2/20 | 0.59 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.59 |
| ▸ | DPP4 | P27487 | 2/20 | 0.49 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PTPRS | Q13332 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6131745 | 0.98 | CD38 (0.73) | CD38GLO1SNCAEGFRKDR | |
| Luteolinidin SCHEMBL676807 | 0.85 | CD38 (0.97) | CD38GLO1SNCAEGFRKDR | |
| Hydrochloric Acid SCHEMBL29413086 | 0.85 | CD38 (0.73) | CD38GLO1SNCAEGFRKDR | |
| Hydrochloric Acid SCHEMBL1366891 | 0.85 | CD38 (0.73) | CD38GLO1SNCAEGFRKDR | |
| Hydrochloric Acid SCHEMBL29392598 | 0.85 | CD38 (0.73) | CD38GLO1SNCAEGFRKDR | |
| Hydrochloric Acid SCHEMBL11317960 | 0.83 | CD38 (0.71) | CD38GLO1SNCAEGFRKDR | |
| Luteolinidin SCHEMBL30159678 | 0.83 | CD38 (1.00) | CD38GLO1SNCAEGFRKDR | |
| Luteolinidin SCHEMBL676808 | 0.83 | CD38 (1.00) | CD38GLO1SNCAEGFRKDR | |
| SCHEMBL5692415 | 0.83 | CD38 (0.76) | CD38GLO1SNCAEGFRKDR | |
| SCHEMBL11155009 | 0.81 | CD38 (0.69) | CD38GLO1SNCAEGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1172090-B1 | Skin dyeing compositions comprising dihydroxyacetone and a flavylium salt non substituted in position 3 | OREAL (FR) | 2005-03-09 | — | — | EP | claimed |
| EP-1172093-B1 | Compositions for coloring the skin containing flavylium salt compounds unsubstituted in position 3 and an organomodified silicone | OREAL (FR) | 2004-12-01 | — | — | EP | claimed |
| EP-1172092-B1 | Compositions for coloring the skin containing at least one UV filter and flavylium salt compounds unsubstituted in position 3 | OREAL (FR) | 2004-09-15 | — | — | EP | claimed |
| CN-103826626-A | Use of epigallocatechin gallate as an antiviral agent against infections by the hepatitis c virus | CENTRE NAT RECH SCIENT | 2014-05-28 | — | — | CN | disclosed |
| US-20140088184-A1 | Use of Epigallocatechin Gallate as an Antiviral Agent against infections by the Hepatitis C Virus | INSTITUT PASTEUR DE LILLE (FR) | 2014-03-27 | — | — | US | disclosed |
| EP-2691091-A1 | USE OF EPIGALLOCATECHIN GALLATE AS AN ANTIVIRAL AGENT AGAINST INFECTIONS BY THE HEPATITIS C VIRUS | Centre National de la Recherche Scientifique (CNRS) (FR) | 2014-02-05 | — | — | EP | disclosed |
| WO-2012130893-A1 | USE OF EPIGALLOCATECHIN GALLATE AS AN ANTIVIRAL AGENT AGAINST INFECTIONS BY THE HEPATITIS C VIRUS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088184-A1 | Use of Epigallocatechin Gallate as an Antiviral Agent against infections by the Hepatitis C Virus | GTF3C3, GTF3C4, GTF3C1 | CD38 2367/4885GLO1 97/4885SNCA 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.